Tag

Boston Scientific

All articles tagged with #boston scientific

business1 month ago•131 min saved

Yields climb and markets wobble as Boston Scientific slides and Qualcomm advances

Higher U.S. Treasury yields are pressuring profits and weighing on stocks, with Boston Scientific dropping 5.9% after a cybersecurity outage foul‑up that could dent Q3 and full‑year 2026 forecasts, and Novartis tumbling 13.9% on a disappointing therapy study. Qualcomm rose 3.2% after announcing a large‑scale AI data‑center collaboration with Amazon. Overseas, Japan’s Nikkei fell about 1.7% as exporters fret the stronger yen ahead of a Bank of Japan meeting, while China’s exports jumped 25% year‑over‑year in August; the day underscores a global market mix of growth signals, currency moves, and central‑bank expectations.

via AP News|

#boston-scientific #business #markets

healthcare1 month ago•17 min saved

Boston Scientific pulls Imager II catheters over tip-detachment risk

Boston Scientific is discontinuing its Imager II Angiographic Catheters after a manufacturing issue could cause the catheter tip to detach; the FDA issued an early alert, two serious injuries have been reported, and healthcare facilities are instructed to stop using or distributing the devices and verify inventory using universal product numbers as the company removes the product from the market.

via MedTech Dive|

#boston-scientific #fda-alert #healthcare

technology1 month ago•18 min saved

Boston Scientific hit by global cyberattack halting orders and shipments

Boston Scientific disclosed a cyberattack that disrupted its IT systems and global order-processing/shipping, with the full impact still unknown. The company activated response protocols and is investigating with third‑party cybersecurity experts, while its stock slid on the news and executives assess potential material impacts amid a wave of medtech cyber incidents.

via MedTech Dive|

#boston-scientific #cyberattack #medtech

businessfinancial-news1 month ago•2 min saved

Boston Scientific battles a global cyber outage and ongoing investigation

Boston Scientific disclosed a cybersecurity incident that triggered a global network outage, disrupting IT systems and potentially delaying orders and shipments. The company activated incident response, is investigating with third-party cybersecurity experts, and has not yet determined a material impact or restoration timeline. The outage affected its Irish plants and employees, with Irish operations mentioned in a notice; shares declined more than 3% in pre-market trading as the investigation continues.

via MassDevice|

#boston-scientific #businessfinancial-news #cybersecurity-incident

business1 month ago•1 min saved

Cyberattack cripples Boston Scientific operations, shipments stall and stock slides

Boston Scientific disclosed a cyberattack that disrupted access to its information systems and shipment services, delaying orders and leaving restoration timelines unclear; the news pushed the stock down about 4.5% as analysts warned that it could take weeks to resume normal operations and protect near-term sales.

via CNBC|

#boston-scientific #business #cyberattack

business2 months ago•16 min saved

Boston Scientific unveils restructuring plan with up to $800 million in charges

Boston Scientific announced a global restructuring to streamline its supply chain and organization, targeting about $700–$800 million in pre-tax charges with completion by 2029. The plan includes transferring manufacturing lines, severance and other costs, while aiming to save roughly $500 million in gross pre-tax expenses to reinvest in growth; the move follows softer performance in electrophysiology and Watchman, and the company expects headcount reductions but will still hire in growth areas.

via MedTech Dive|

#boston-scientific #business #charges

business4 months ago•7 min saved

Boston Scientific backs MiRus with $1.5B stake, eyes exclusive TAVR deal

Boston Scientific announced a $1.5 billion investment for about 34% equity in MiRus and secured an exclusive option to acquire MiRus’ SIEGEL balloon-expandable transcatheter aortic valve replacement (TAVR) system, built on a proprietary nickel-free rhenium alloy. The device features dry porcine tissue leaflets and a nitric oxide-coated rhenium frame with high radial strength, and it is designed for precise placement via an 8 French expandable sheath. MiRus has launched the STAR pivotal trial evaluating three valve sizes in up to 1,025 patients. The deal is expected to be immaterial to 2026 EPS, with Boston Scientific able to move to 100% ownership via additional payments totaling up to $3 billion upon milestones.

via www.bostonscientific.com|

#boston-scientific #business #mirus

business8 months ago•30 min saved

Boston Scientific posts stronger-than-expected 2025 results, lifts 2026 outlook

Boston Scientific reported Q4 2025 net sales of $5.286 billion, up 15.9% year over year, with GAAP net income of $672 million ($0.45 per share) and adjusted EPS of $0.80. For all of 2025, net sales totaled $20.074 billion (up 19.9%), GAAP net income was $2.898 billion ($1.94 per share), and adjusted EPS was $3.06. For 2026, the company guides net sales growth of about 10.5–11.5% on a reported basis (10.0–11.0% organic) and adjusted EPS of $3.43–$3.49, plus Q1 2026 guidance of 10.5–12.0% net sales growth (8.5–10.0% organic) and EPS $0.78–$0.80. The release also notes ongoing product approvals, trials, and strategic acquisitions (e.g., Penumbra, Valencia Technologies) and the discontinuation of ACURATE neo2/Prime valve sales.

via www.bostonscientific.com|

#2026-guidance #boston-scientific #business

business8 months ago•5 min saved

Boston Scientific to Acquire Penumbra for $14.5 Billion, Expanding Stroke Tech

Boston Scientific signed a cash-and-stock deal to acquire Penumbra for about $14.5 billion, valuing Penumbra at $374 per share and aiming to close later this year pending approvals. Penumbra’s portfolio spans neurovascular and vascular devices, including thrombectomy systems, potentially broadening Boston Scientific’s growth in high-potential markets. Financing consists of roughly 73% cash and 27% stock, with an expected near-term EPS dilution followed by accretion as synergies materialize.

via MassDevice|

#boston-scientific #business #medical-devices

business8 months ago•11 min saved

Boston Scientific set to buy Penumbra for $14.5B, expanding vascular devices portfolio

Boston Scientific plans to acquire Penumbra for about $14.5 billion in cash and stock, gaining Penumbra’s thrombectomy and embolization devices to broaden its vascular portfolio. The deal values Penumbra at $374 per share and is expected to close in 2026 pending shareholder and regulatory approvals, with Penumbra generating about $1.4 billion in revenue for 2025. Analysts say the price is fair and the acquisition aligns with a trend of medtech consolidation.

via MedTech Dive|

#boston-scientific #business #manda

business8 months ago•13 min saved

Boston Scientific to acquire Penumbra in $14.5B push into thrombectomy and neurovascular care

Boston Scientific announced a definitive agreement to acquire Penumbra in a cash-and-stock deal valued at about $14.5 billion (Penumbra at $374/share), creating a scaled entry into mechanical thrombectomy and neurovascular therapies. The transaction finances roughly 73% cash and 27% Boston Scientific stock (about $11 billion cash financed with cash on hand and new debt) and is expected to close in 2026 pending stockholder and regulatory approvals. Penumbra reported about $1.4 billion in revenue for 2025. Penumbra stockholders may elect cash or Boston Scientific shares; Adam Elsesser plans to take Boston Scientific stock for all his Penumbra shares. The deal is dilutive to GAAP earnings in the near term and to adjusted EPS in the near term, with accretion expected in later years.

via PR Newswire|

#acquisition #boston-scientific #business

business-and-finance2 years ago•3 min saved

Boston Scientific's $3.7 Billion Acquisition of Axonics

Boston Scientific has agreed to acquire Axonics for approximately $3.7 billion, aiming to strengthen its urology business and expand into the high-growth sacral neuromodulation market. Axonics, based in California, develops neuromodulation systems for urinary and bowel dysfunction treatment. The acquisition is expected to be completed in the first half of 2024, with Boston Scientific projecting a highly accretive impact on its urology business in 2024. This move aligns with Boston Scientific's strategy of pursuing M&A to reinforce category leadership and enter faster growth markets.

via Mass Device|

#acquisition #axonics #boston-scientific

business2 years ago•0 min saved

Boston Scientific's $3.7 Billion Acquisition of Axonics

Boston Scientific has announced its acquisition of Axonics for approximately $3.7 billion in cash, with the deal aimed at expanding its portfolio to better serve urologists. The agreement values Axonics at $71 per share, giving the company an equity value of $3.7 billion and an enterprise value of $3.4 billion.

via The Wall Street Journal|

#acquisition #axonics #boston-scientific

business2 years ago•6 min saved

"Boston Scientific to Acquire Axonics, Inc. in New Agreement"

Boston Scientific has agreed to acquire Axonics, Inc. for approximately $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' product portfolio includes sacral neuromodulation (SNM) therapy systems for overactive bladder and fecal incontinence, with the recent FDA approval of its fourth-generation neurostimulator. The acquisition is expected to strengthen Boston Scientific's ability to serve urologists and provide opportunities to expand access to care for patients. The transaction is anticipated to be completed in the first half of 2024 and is expected to have a highly accretive impact on Boston Scientific's urology business in 2024.

via PR Newswire|

#acquisition #axonics #boston-scientific

healthcare3 years ago•5 min saved

Boston Scientific Acquires Relievant Medsystems for $850M in Back Pain Ablation Tech Deal

Boston Scientific has announced its agreement to acquire Relievant Medsystems, a medical technology company specializing in treating chronic low back pain. The acquisition will expand Boston Scientific's neuromodulation portfolio and provide more treatment options for individuals with vertebrogenic pain. The transaction includes an upfront cash payment of $850 million, with additional contingent payments based on sales performance. The Intracept Intraosseous Nerve Ablation System developed by Relievant is the only FDA-cleared system for vertebrogenic pain and offers a minimally invasive outpatient procedure. The deal is expected to close in the first half of 2024.

via PR Newswire|

#acquisition #boston-scientific #chronic-low-back-pain